|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Noone AM, Cronin KA, Altekruse SF,
Howlader N, Lewis DR, Petkov VI and Penberthy L: Cancer incidence
and survival trends by subtype using data from the surveillance
epidemiology and end results program, 1992–2013. Cancer Epidemiol
Biomarkers Prev. 26:632–641. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: Ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Verma S, Miles D, Gianni L, Krop IE,
Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, et al:
Trastuzumab emtansine for HER2-positive advanced breast cancer. N
Engl J Med. 367:1783–1791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fu Z, Li S, Han S, Shi C and Zhang Y:
Antibody drug conjugate: The ‘biological missile’ for targeted
cancer therapy. Signal Transduct Target Ther. 7:932022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krop IE, Kim SB, González-Martín A,
LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC and Wildiers H;
TH3RESA study collaborators, : Trastuzumab emtansine versus
treatment of physician's choice for pretreated HER2-positive
advanced breast cancer (TH3RESA): A randomised, open-label, phase 3
trial. Lancet Oncol. 15:689–699. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perez EA, Barrios C, Eiermann W, Toi M, Im
YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA III, et
al: Trastuzumab emtansine with or without pertuzumab versus
trastuzumab with taxane for human epidermal growth factor receptor
2-positive advanced breast cancer: Final results from MARIANNE.
Cancer. 125:3974–3984. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gennari A, André F, Barrios CH, Cortés J,
de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz
SA, et al: ESMO clinical practice guideline for the diagnosis,
staging and treatment of patients with metastatic breast cancer.
Ann Oncol. 32:1475–1495. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
National Comprehensive Cancer Network, .
Breast cancer version 4.2022, 2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfAugust
31–2022
|
|
10
|
Diéras V, Miles D, Verma S, Pegram M,
Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, et al:
Trastuzumab emtansine versus capecitabine plus lapatinib in
patients with previously treated HER2-positive advanced breast
cancer (EMILIA): A descriptive analysis of final overall survival
results from a randomised, open-label, phase 3 trial. Lancet Oncol.
18:732–742. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Krop IE, Kim SB, Martin AG, LoRusso PM,
Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M and Wildiers
H: Trastuzumab emtansine versus treatment of physician's choice in
patients with previously treated HER2-positive metastatic breast
cancer (TH3RESA): Final overall survival results from a randomised
open-label phase 3 trial. Lancet Oncol. 18:743–754. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Montemurro F, Ellis P, Anton A, Wuerstlein
R, Delaloge S, Bonneterre J, Quenel-Tueux N, Linn SC, Irahara N,
Donica M, et al: Safety of trastuzumab emtansine (T-DM1) in
patients with HER2-positive advanced breast cancer: Primary results
from the KAMILLA study cohort 1. Eur J Cancer. 109:92–102. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu F, Ke J and Song Y: T-DM1-induced
thrombocytopenia in breast cancer patients: New perspectives.
Biomed Pharmacother. 129:1104072020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Girish S, Gupta M, Wang B, Lu D, Krop IE,
Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, et al: Clinical
pharmacology of trastuzumab emtansine (T-DM1): An antibody-drug
conjugate in development for the treatment of HER2-positive cancer.
Cancer Chemother Pharmacol. 69:1229–1240. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang SC, Capra CL, Ajebo GH, Meza-Junco J,
Mairs S, Craft BS, Zhu X, Maihle N and Hillegass WB: Systemic
toxicities of trastuzumab-emtansine predict tumor response in HER2+
metastatic breast cancer. Int J Cancer. 149:909–916. 2021.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tataroglu Ozyukseler D, Basak M, Ay S,
Koseoglu A, Arıcı S, Oyman A, Sürmeli H, Turan M, Turan N, Odabaş H
and E Yıldırım M: Prognostic factors of ado-trastuzumab emtansine
treatment in patients with metastatic HER-2 positive breast cancer.
J Oncol Pharm Pract. 27:547–554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yardley DA, Krop IE, LoRusso PM, Mayer M,
Barnett B, Yoo B and Perez EA: Trastuzumab emtansine (T-DM1) in
patients With HER2-positive metastatic breast cancer previously
treated with chemotherapy and 2 or more HER2-targeted agents:
Results from the T-PAS expanded access study. Cancer J. 21:357–364.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
U.S. Food and Drug Administration (FDA), .
FDA approves ado-trastuzumab emtansine for early breast cancer.
FDA, Silver Spring, MD. 2019.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ado-trastuzumab-emtansine-early-breast-cancer
|
|
19
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Allison KH, Hammond MEH, Dowsett M,
McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR,
Chavez-MacGregor M, Perlmutter J, et al: Estrogen and progesterone
receptor testing in breast cancer: ASCO/CAP guideline update. J
Clin Oncol. 38:1346–1366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American society of clinical oncology/college of
American pathologists clinical practice guideline focused update.
Arch Pathol Lab Med. 142:1364–1382. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
NCI, . Common terminology criteria for
adverse events v5.0, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5×11.pdfApril
19–2020
|
|
24
|
Fabi A, De Laurentiis M, Caruso M, Valle
E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M,
Rossello R, et al: Efficacy and safety of T-DM1 in the
‘common-practice’ of HER2+ advanced breast cancer setting: A
multicenter study. Oncotarget. 8:64481–64489. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yeo W, Luk MY, Soong IS, Yuen TY, Ng TY,
Mo FK, Chan K, Wong SY, Tsang J, Leung C, et al: Efficacy and
tolerability of trastuzumab emtansine in advanced human epidermal
growth factor receptor 2-positive breast cancer. Hong Kong Med J.
24:56–62. 2018.PubMed/NCBI
|
|
26
|
Modi ND, Sorich MJ, Rowland A, McKinnon
RA, Koczwara B, Wiese MD and Hopkins AM: Predicting
thrombocytopenia in patients with breast cancer treated with
ado-trastuzumab emtansine. Clin Breast Cancer. 20:e220–e228. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang E, Rowland A, McKinnon RA, Sorich MJ
and Hopkins AM: Effect of early adverse events resulting in
ado-trastuzumab emtansine dose adjustments on survival outcomes of
HER2+ advanced breast cancer patients. Breast Cancer Res Treat.
178:473–477. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thon JN, Devine MT, Begonja AJ, Tibbitts J
and Italiano JE Jr: High-content live-cell imaging assay used to
establish mechanism of trastuzumab emtansine (T-DM1)-mediated
inhibition of platelet production. Blood. 120:1975–1984. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao H, Gulesserian S, Ganesan SK, Ou J,
Morrison K, Zeng Z, Robles V, Snyder J, Do L, Aviña H, et al:
Inhibition of megakaryocyte differentiation by antibody-drug
conjugates (ADCs) is mediated by macropinocytosis: Implications for
ADC-induced thrombocytopenia. Mol Cancer Ther. 16:1877–1886. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong
V, Tsai CM, Lee JS, Kang JH, Chan KC, Perez-Moreno P, et al:
First-line erlotinib therapy until and beyond response evaluation
criteria in solid tumors progression in asian patients with
epidermal growth factor receptor mutation-positive non-small-cell
lung cancer: The ASPIRATION study. JAMA Oncol. 2:305–312. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haddad R, Concha-Benavente F, Blumenschein
G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes
EE, Worden F, et al: Nivolumab treatment beyond RECIST-defined
progression in recurrent or metastatic squamous cell carcinoma of
the head and neck in CheckMate 141: A subgroup analysis of a
randomized phase 3 clinical trial. Cancer. 125:3208–3218. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H,
Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, et al: Continuing
EGFR-TKI beyond radiological progression in patients with advanced
or recurrent, EGFR mutation-positive non-small-cell lung cancer: An
observational study. ESMO Open. 2:e0002142017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Escudier B, Motzer RJ, Sharma P, Wagstaff
J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski
PG, et al: Treatment beyond progression in patients with advanced
renal cell carcinoma treated with nivolumab in CheckMate 025. Eur
Urol. 72:368–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ge X, Zhang Z, Zhang S, Yuan F, Zhang F,
Yan X, Han X, Ma J, Wang L, Tao H, et al: Immunotherapy beyond
progression in patients with advanced non-small cell lung cancer.
Transl Lung Cancer Res. 9:2391–2400. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Czarnecka AM, Sobczuk P, Rogala P, Świtaj
T, Placzke J, Kozak K, Mariuk-Jarema A, Spałek M, Dudzisz-Śledź M,
Teterycz P, et al: Efficacy of immunotherapy beyond RECIST
progression in advanced melanoma: A real-world evidence. Cancer
Immunol Immunother. 71:1949–1958. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bennouna J, Sastre J, Arnold D, Österlund
P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C,
et al: Continuation of bevacizumab after first progression in
metastatic colorectal cancer (ML18147): A randomised phase 3 trial.
Lancet Oncol. 14:29–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guven DC, Yekeduz E, Erul E, Yazgan SC,
Sahin TK, Karatas G, Aksoy S, Erman M, Yalcin S, Urun Y and
Kilickap S: The benefit of treatment beyond progression with immune
checkpoint inhibitors: A multi-center retrospective cohort study. J
Cancer Res Clin Oncol. 149:3599–3606. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu Y, Zhou L, Chen Y, Liao B, Ye D, Wang
K and Li H: Hypertension as a prognostic factor in metastatic renal
cell carcinoma treated with tyrosine kinase inhibitors: A
systematic review and meta-analysis. BMC Urol. 19:492019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ou SHI, Tong WP, Azada M, Siwak-Tapp C, Dy
J and Stiber JA: Heart rate decrease during crizotinib treatment
and potential correlation to clinical response. Cancer.
119:1969–1975. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bar-Ad V, Zhang QE, Harari PM, Axelrod R,
Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote RL, et
al: Correlation between the severity of cetuximab-induced skin rash
and clinical outcome for head and neck cancer patients: The RTOG
experience. Int J Radiat Oncol Biol Phys. 95:pp1346–1354. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Holch JW, Held S, Stintzing S, Fischer von
Weikersthal L, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C,
Kullmann F, et al: Relation of cetuximab-induced skin toxicity and
early tumor shrinkage in metastatic colorectal cancer patients:
Results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). Ann
Oncol. 31:72–78. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vici P, Pizzuti L, Michelotti A, Sperduti
I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini
D, et al: A retrospective multicentric observational study of
trastuzumab emtansine in HER2 positive metastatic breast cancer: A
real-world experience. Oncotarget. 8:56921–56931. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hopkins AM, Rowland A, Logan JM and Sorich
MJ: Primary predictors of survival outcomes for HER2-positive
advanced breast cancer patients initiating ado-trastuzumab
emtansine. Breast. 46:90–94. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Blumenthal GM, Gong Y, Kehl K,
Mishra-Kalyani P, Goldberg KB, Khozin S, Kluetz PG, Oxnard GR and
Pazdur R: Analysis of time-to-treatment discontinuation of targeted
therapy, immunotherapy, and chemotherapy in clinical trials of
patients with non-small-cell lung cancer. Ann Oncol. 30:830–838.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dall'Olio FG, Marabelle A, Caramella C,
Garcia C, Aldea M, Chaput N, Robert C and Besse B: Tumour burden
and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol.
19:75–90. 2022. View Article : Google Scholar : PubMed/NCBI
|
